Abstract
Poorly differentiated endocrine carcinomas (PDEC) are usually treated with cisplatin-based chemotherapy regimens. We here present a case with a dramatic response (both radiologically and biochemically) to the combination of temozolomide and bevacizumab, after failure of cisplatin and etoposide, with continued tumor shrinkage at 5 months. Temozolomide combined with bevacizumab might be a good treatment option in PDEC, perhaps even in a first-line setting. Prospective studies to answer this are warranted.
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Carcinoma, Neuroendocrine / drug therapy*
-
Carcinoma, Neuroendocrine / physiopathology
-
Carcinoma, Neuroendocrine / secondary
-
Dacarbazine / administration & dosage
-
Dacarbazine / analogs & derivatives
-
Female
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / physiopathology
-
Liver Neoplasms / secondary
-
Salvage Therapy / methods*
-
Temozolomide
Substances
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Dacarbazine
-
Temozolomide